Empowering Mass Spec for Biotech and Beyond
About Andson: (TL;DR video about us: https://youtu.be/wMyAikoQkXE)
Andson Biotech is developing a microfluidic platform enabling rapid sample cleanup for mass spectrometry applications. Mass spectrometry is a gold-standard chemical analysis tool, but it remains limited in utility due to the complex workflows associated with going from raw sample to analysis. Our flagship product, the DynaCHIP, enables simple, on-demand mass spectrometric analysis with easy-to-use interfaces that democratize mass spectrometry from lab to market.
Andson Biotech was spun out of Georgia Tech and is supported by Y Combinator and Merck Digital Sciences Studio. We are a seed-stage startup, so every role has the chance for growth.
Total raised
$8.7M
Last stage
Series A
Investors
Mason Chilmonczyk
Mason is the co-founder and CEO of Andson Biotech, an academic spinout based on Mason's research at the Georgia Institute of Technology. At Andson, Mason is driving the company's mission to develop novel methodologies for advanced biomanufacturing discovery and monitoring. Mason is formally trained as a mechanical engineer with a BS from the University of South Florida ('14) and an MS and PhD from Georgia Tech ('17, '20).
LinkedInAndrei Fedorov
Professor who co-founded Andson Biotech with expertise in biotools for mass spectrometry sample prep and analytics.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.